ACC 2026
Targeting Lower Cholesterol Cuts Cardiac Events by a Third, First Head-to- Head Trial Vindicates Aggressive LDL-C Goals
Ez-PAVE trial: aiming for LDL-C below 55 mg/dL rather than
Mukul Ayachit
April 13, 2026
Ez-PAVE trial: aiming for LDL-C below 55 mg/dL rather than
CHAMPION-AF trial: Left atrial appendage closure proves non-inferior to NOACs
VESALIUS-CV subanalysis: evolocumab reduces major adverse cardiac events by 31%
Phase 2 trial of tonlamarsen in resistant hypertension: the drug’s
STEMI-DTU trial: Delayed reperfusion with LV unloading shows no significant
Long-awaited survival data from the ARTO trial have confirmed that